LifeSci Venture Partners
Venture capitalNew York · Series A–Late Stage · 2 people tracked
Also known as LIFESCI VENTURE MANAGEMENT, LLC
Find your way into LifeSci Venture Partners
764 people in our graph share verified history with the LifeSci Venture Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
LifeSci Venture Partners focuses on the life sciences sector, backing biotech and pharmaceutical companies where its team brings clinical, scientific, and investment expertise. The firm emphasizes long-term conviction and hands-on partnership, playing an integral role in company formation and launch, guiding founders through investor storytelling, outreach, and closing strategies, and supporting portfolio companies over multiple ventures and across the investment lifecycle.
Source: firm website, verified Sep 15, 2026.
Team · 2 people
from the firm's website & public directories
What they invest in
from 13 of 14 portfolio companiesBiotech ×12Healthtech ×5Medical Devices ×5Deep Tech ×3Digital Health ×3Hardware ×1New Materials ×1
HQs:United States×11
Investments · 14 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 32020 · 26 dated
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
Co-investorsAndreessen HorowitzARCH Venture PartnersEvolution VC PartnersFrazier Life SciencesCity Hill VenturesColt Ventures
BiotechTel Aviv
Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)
PartnerPaul Yook· solo GP
Co-investorsHEALTHCARE ROYALTY PARTNERS
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)
BoardDonald Tang(Director)
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNew Enterprise Associates (NEA)+10 more
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsLongitude CapitalConnecticut InnovationsOUP (Osage University Partners)SR One Capital Managementabrdn plcInvus
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.
BiotechHealthtechMedical Devices
Co-investorsArboretum VenturesMaverick Ventures IsraelVisionary VenturesCatalio Capital ManagementJohnson & Johnson Innovation – JJDCSequoia Capital+1 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.
Digital HealthHardwareMedical Devices
Jared Tangney(Founder)inRich Yangin
Co-investorsAble PartnersAlpha Wave GlobalAphelion CapitalAverin CapitalBOLD LongevityHikma Ventures+2 more
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalBeyond CapitalBioBritJDRF T1D FundAphelion CapitalHikma Ventures+1 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsBain Capital Life SciencesCasdin CapitalVenrock Healthcare Capital Partners
Company whose formation and launch the LifeSci team supported.
BiotechHealthtechSummit, US
Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)
BoardGerry Brunk(Director)in
PartnerPaul Yook· solo GP
Co-investorsLumira Ventures
Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids.
BiotechDeep TechNew Materials
PartnerPaul Yook· solo GP
Co-investorsConnecticut InnovationsDuke Capital PartnersLongley CapitalPrime Movers Lab
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
4 IPOsErascaNASDAQ: ERASRedHill Biopharma LtdNASDAQ: RDHLSenti BiosciencesNASDAQ: SNTIVeradermicsNYSE: MANE
Portfolio news
latest coverage across their companiesSenti Biosciences · kalkine.com.au · Jul 31, 2026
Biolinq · fiercebiotech.com · Sep 29, 2025
Biolinq · fiercebiotech.com · Sep 29, 2025
Frequently asked questions
- How many investments has LifeSci Venture Partners made?
- LifeSci Venture Partners has 14 tracked investments, 4 of which have exited.
- What stage does LifeSci Venture Partners invest at?
- LifeSci Venture Partners invests at the Series A, Series B, Series C, Late Stage stages.
- What sectors does LifeSci Venture Partners focus on?
- LifeSci Venture Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is LifeSci Venture Partners located?
- LifeSci Venture Partners is headquartered in New York, US.
- Does LifeSci Venture Partners lead rounds?
- LifeSci Venture Partners typically participates in rounds rather than leading them.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.